Stephanie Richards

Stephanie Richards is a partner in Goodwin’s nationally recognized Life Sciences group, counseling private and public companies at all life cycle stages as well as leading venture capital firms and investment banks across the life sciences industry.

Stephanie advises clients on startup and formation matters, venture capital financings, initial public offerings and capital markets transactions, mergers and acquisitions, and other complex transactions. She also represents publicly traded biotechnology companies in ongoing corporate matters, including SEC compliance and corporate governance matters. She joined Goodwin in 2018.

Stephanie's recent client representations include the following:

• Ikena Oncology in its announced PIPE in connection with its merger with Inmagene Biopharmaceuticals 
• Rapport Therapeutics in its $174.4 million initial public offering and concurrent private placement
• Kazia Therapeutics in its at-the-market offering and equity lines of credit
• Aura Biosciences in its $75.6 million initial public offering, $75 million “at-the-market” offering, $80.4 million follow on offering and $99 million follow on offering
• Disc Medicine in its $137 million follow on offering
• Ikena Oncology in its $133.6 million initial public offering, and in its $100 million “at-the-market” offering and $40 million underwritten offering
• SpringWorks Therapeutics in its $225 million PIPE financing
• Kymera Therapeutics in its $150 million PIPE financing
• Flagship Pioneering in its investment in a PIPE financing by Syros Pharmaceuticals
• Olink Holding AB (publ) in its $264 million initial public offering, $232.5 million secondary public offering, and $80.75 million follow on offering
• iTeos Therapeutics in its $201 million initial public offering
• The underwriters in Tufin Software Technologies’ $107.8 million initial public offering
• The underwriters in Freeline Therapeutics Holdings plc’s $159 million initial public offering
• Xeris Pharmaceuticals in its $85.5 million initial public offering, subsequent debt and equity follow on offerings 
• TCR² Therapeutics in its $75 million initial public offering and subsequent equity follow on offerings

Venture Capital Financings

• Rapport Therapeutics in its $100 million Series A financing and $150 million Series B financing
• Repertoire Immune Medicines in its $189 million Series B financing
• Third Rock Ventures in its investment in Synnovation Therapeutics’ $102 million Series A financing 
• Aura Biosciences in its $80 million Series E financing
• Ikena Oncology in its $120 million Series B financing
• Faze Medicines in its $81 million Series A financing
• Thrive Earlier Detection Corp. in its $110 million Series A financing and $257 million Series B financing
• iTeos Therapeutics in its $125 million Series B financing
• Flagship Pioneering in connection with their company formation and financing related matters
• Third Rock Ventures in connection with their company formation and financing related matters

Mergers and Acquisitions

• Ikena Oncology in its announced merger with Inmagene Biopharmaceuticals
• Fusion Pharmaceuticals in its sale to AstraZeneca
• Alkermes in the spin off of its oncology business into Mural Oncology as a separate public company
• Ikena Oncology in its acquisition of Pionyr Immunotherapeutics
• TCR² Therapeutics in its cross-border sale to Adaptimmune
• Disc Medicine in connection with its reverse merger transaction with Gemini Therapeutics
• Xeris Pharmaceuticals in its cross-border acquisition of Strongbridge Biopharma
• Inzen Therapeutics in its merger with Cygnal Therapeutics
• Valo Health in its announced 2021 deSPAC business combination with Khosla Ventures Acquisition Co.
• Cogen Immune Medicines in its merger with Torque Therapeutics
• ProKidney and its lead investor, Pablo Legorreta, founder and CEO of Royalty Pharma, in the acquisition of inRegen and Twin City Bio, LLC
• Adhaere Pharmaceuticals in its sale to Gossamer Bio

Stephanie has been recognized by The Best Lawyers in America for her work in Corporate Law 2025.